The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota
- PMID: 35319337
- PMCID: PMC8959509
- DOI: 10.1080/19490976.2022.2052698
The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota
Abstract
Clostridioides difficile is the most prevalent pathogen of nosocomial diarrhea. In the United States, over 450,000 cases of C. difficile infection (CDI), responsible for more than 29,000 deaths, are reported annually in recent years. Because of the emergence of hypervirulent strains and strains less susceptible to vancomycin and fidaxomicin, new therapeutics other than antibiotics are urgently needed. The gut microbiome serves as one of the first-line defenses against C. difficile colonization. The use of antibiotics causes gut microbiota dysbiosis and shifts the status from colonization resistance to infection. Hence, novel CDI biotherapeutics capable of reconstituting normal gut microbiota have become a focus of drug development in this field.
Keywords: Clostridioides difficile; biotherapeutics; dysbiosis; microbiota; reconstitution.
Conflict of interest statement
No potential conflict of interest was reported by the author(s).
Figures
Similar articles
-
Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.Lett Appl Microbiol. 2022 Sep;75(3):526-536. doi: 10.1111/lam.13664. Epub 2022 Feb 11. Lett Appl Microbiol. 2022. PMID: 35119124 Free PMC article. Review.
-
The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin.J Infect Chemother. 2020 May;26(5):483-491. doi: 10.1016/j.jiac.2019.12.020. Epub 2020 Mar 9. J Infect Chemother. 2020. PMID: 32165071
-
The vanRCd Mutation 343A>G, Resulting in a Thr115Ala Substitution, Is Associated with an Elevated Minimum Inhibitory Concentration (MIC) of Vancomycin in Clostridioides difficile Clinical Isolates from Florida.Microbiol Spectr. 2023 Jun 15;11(3):e0377722. doi: 10.1128/spectrum.03777-22. Epub 2023 May 1. Microbiol Spectr. 2023. PMID: 37125917 Free PMC article.
-
[Nosocomial gastrointestinal infections and Clostridioides difficile].Dtsch Med Wochenschr. 2025 Feb;150(4):149-156. doi: 10.1055/a-2303-3321. Epub 2025 Jan 29. Dtsch Med Wochenschr. 2025. PMID: 39879969 Review. German.
-
Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02112-17. doi: 10.1128/AAC.02112-17. Print 2018 May. Antimicrob Agents Chemother. 2018. PMID: 29463537 Free PMC article.
Cited by
-
Clostridium butyricum MIYAIRI 588 contributes to the maintenance of intestinal microbiota diversity early after haematopoietic cell transplantation.Bone Marrow Transplant. 2024 Jun;59(6):795-802. doi: 10.1038/s41409-024-02250-1. Epub 2024 Mar 2. Bone Marrow Transplant. 2024. PMID: 38431763 Free PMC article.
-
Bioengineered Probiotics for Clostridioides difficile Infection: An Overview of the Challenges and Potential for This New Treatment Approach.Probiotics Antimicrob Proteins. 2025 Apr;17(2):763-780. doi: 10.1007/s12602-024-10398-x. Epub 2024 Nov 12. Probiotics Antimicrob Proteins. 2025. PMID: 39531149 Review.
-
Modulation of multiple sclerosis risk and pathogenesis by the gut microbiota: Complex interactions between host genetics, bacterial metabolism, and diet.Immunol Rev. 2024 Aug;325(1):131-151. doi: 10.1111/imr.13343. Epub 2024 May 8. Immunol Rev. 2024. PMID: 38717158 Free PMC article. Review.
-
Gut Microbiota and Clostridium difficile: What We Know and the New Frontiers.Int J Mol Sci. 2022 Nov 1;23(21):13323. doi: 10.3390/ijms232113323. Int J Mol Sci. 2022. PMID: 36362106 Free PMC article. Review.
-
Microbiota of the gastrointestinal tract: Friend or foe?World J Gastroenterol. 2023 Jan 7;29(1):19-42. doi: 10.3748/wjg.v29.i1.19. World J Gastroenterol. 2023. PMID: 36683718 Free PMC article. Review.
References
-
- Hall IC, Denver T, Denver T, Denver T, Denver T.. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. American Journal of Dieseases of Children. 1935;49(2):390–18. doi:10.1001/archpedi.1935.01970020105010. - DOI
-
- Ozaki E, Kato H, Kita H, Karasawa T, Maegawa T, Koino Y, Matsumoto K, Takada T, Nomoto K, Tanaka R, et al. Clostridium difficile colonization in healthy adults: transient colonization and correlation with enterococcal colonization. J Med Microbiol. 2004;53(2):167–172. doi:10.1099/jmm.0.05376-0. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources